A short animation based on research by Professor Colin Espie, explores how ‘better sleep’ can fundamentally improve our health and wellbeing

Research involving the Nuffield Department of Medicine has been highlighted in #NatureMedicine as one of the 11 clinical trials expected to shape medicine in 2026. The article names the RIO Trial, testing long-acting antibodies (3BNC117-LS and 10-1074-LS) for HIV. The study is exploring whether these antibodies could offer long-lasting treatment, replacing the need for daily medication, and whether they may also boost the body’s own immune response to help control HIV long-term.   This work brings together researchers from the Nuffield Department of Medicine, The Rockefeller University, and Imperial College London, and reflects how global collaboration across academic institutions has the potential to turn research into real-world benefits for people. Congratulations to John Frater, Professor of Infectious Diseases NDM, his team, and research partners at Rockefeller and Imperial, on this recognition.   #UniversityOfOxford #HIVResearch #ClinicalTrials #GlobalHealth #ResearchCollaboration #NatureMedicine University of Oxford   Read the full article https://lnkd.in/eJ9V2wsd

New RDM research reveals how prior hypoglycaemia weakens a key hormonal defence.

https://thesleepcharity.org.uk/the-5-principles-of-good-sleep-health/ When we strip things down to life’s essentials, we discover that sleep gives us the capability to live our best lives. We need…

People tend to regain weight rapidly after stopping weight-loss drugs – and faster than after ending behavioural weight loss programmes – according to a new systematic review and meta-analysis from department researchers published in The BMJ today.

The Chancellor will honour distinguished individuals at the Sheldonian Theatre in February.

New weight loss jabs work brilliantly – but only while you’re taking them. The rebound is fast, and the cost-effectiveness unclear.

This survey asks questions about endometriosis-associated pain and some of the ways you think about your body. It aims to contribute to a developing field of psychological understanding and treatment…

Experts from Cancer Research UK share how through world-class research, we can better understand and tackle the impacts of cancer inequalities

FORTIFY is an international clinical trial to test a potential treatment for people with coronary inflammation. The first patient in Europe has been recruited by the team at the Acute Multidisciplinary Imaging and Interventional Centre (AMIIC). AMIIC is a state-of-the art facility in the Radcliffe Department of Medicine linking interventional, non-invasive imaging and artificial intelligence/big data capabilities.

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message…

Together with a group of Oxford researchers, Mark Coles, Professor of Immunology at the Kennedy Institute, will co-lead the Enabling Next-generation AI for a Bioscience-Led Economy (ENAIBLE) initiative.

A study published recently in The Lancet Psychiatry has unveiled a new approach to identifying individuals at risk of developing psychotic disorders or bipolar disorder.

Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving landscape of genomics and genetic therapies, and…

The King’s New Year Honours 2026 have been announced, marking the achievements and service of extraordinary people across the UK, including members of the University of Oxford.

At this time of year, we are all busy and it’s easy to be distracted, especially when you are trying to get half a billion presents ready. But that’s why it’s especially important to be on the look out for malicious cyber activity – just ask Mary Christmas...